AAAAAA
Results: 1-25/29
Authors:
Novick, D
Schwartsburd, B
Pinkus, R
Suissa, D
Belzer, I
Sthoeger, Z
Keane, WF
Chvatchko, Y
Kim, SH
Fantuzzi, G
Dinarello, CA
Rubinstein, M
Citation: D. Novick et al., A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensivedecrease of free IL-18, CYTOKINE, 14(6), 2001, pp. 334-342
Authors:
Keane, WF
Citation: Wf. Keane, Metabolic pathogenesis of cardiorenal disease, AM J KIDNEY, 38(6), 2001, pp. 1372-1375
Authors:
Brown, WW
Keane, WF
Citation: Ww. Brown et Wf. Keane, Proteinuria and cardiovascular disease, AM J KIDNEY, 38(4), 2001, pp. S8-S13
Authors:
Keane, WF
Mitch, WE
Fouque, D
Citation: Wf. Keane et al., Advances in nutrition and metabolism in renal disease - 10th InternationalCongress on Nutrition and Metabolism in Renal Disease - Lyon, France - July 6-8, 2000 - Introduction, AM J KIDNEY, 37(1), 2001, pp. S1-S1
Authors:
Keane, WF
Brenner, BM
Mazzu, A
Agro, A
Citation: Wf. Keane et al., The CHORUS (Cerivastatin in heart outcomes in renal disease Understanding survival) protocol: A double-blind, placebo-controlled trial in patients with ESRD, AM J KIDNEY, 37(1), 2001, pp. S48-S53
Authors:
Keane, WF
Citation: Wf. Keane, Progression of renal disease - Introduction, SEM NEPHROL, 21(6), 2001, pp. 533-534
Authors:
Nemoto, T
Burne, MJ
Daniels, F
O'Donnell, MP
Crosson, J
Berens, K
Issekutz, A
Kasiske, BL
Keane, WF
Rabb, H
Citation: T. Nemoto et al., Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure, KIDNEY INT, 60(6), 2001, pp. 2205-2214
Authors:
Nemoto, T
Yokota, N
Keane, WF
Rabb, H
Citation: T. Nemoto et al., Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure, KIDNEY INT, 59(1), 2001, pp. 246-251
Authors:
Hebert, LA
Spetie, DN
Keane, WF
Citation: La. Hebert et al., The urgent call of albuminuria/proteinuria - Heeding its significance in early detection of kidney disease, POSTGR MED, 110(4), 2001, pp. 79
Authors:
Eknoyan, G
Levey, AS
Levin, NW
Keane, WF
Citation: G. Eknoyan et al., The national epidemic of chronic kidney disease - What we know and what wecan do, POSTGR MED, 110(3), 2001, pp. 23-29
Authors:
Brenner, BM
Cooper, ME
de Zeeuw, D
Keane, WF
Mitch, WE
Parving, HH
Remuzzi, G
Snapinn, SM
Zhang, ZX
Shahinfar, S
Citation: Bm. Brenner et al., Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N ENG J MED, 345(12), 2001, pp. 861-869
Authors:
Khan, MA
Collins, AJ
Keane, WF
Citation: Ma. Khan et al., Diabetes in the elderly population, ADV RENAL R, 7(1), 2000, pp. 32
Authors:
Vas, SI
Keane, WF
Citation: Si. Vas et Wf. Keane, Treatment of peritonitis: Update or new course, PERIT DIA I, 20(4), 2000, pp. 384-385
Authors:
Keane, WF
Bailie, GR
Boeschoten, E
Gokal, R
Golper, TA
Holmes, CJ
Kawaguchi, Y
Piraino, B
Riella, M
Vas, S
Citation: Wf. Keane et al., Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update, PERIT DIA I, 20(4), 2000, pp. 396-411
Authors:
Sica, DA
Halstenson, CE
Gehr, TWB
Keane, WF
Citation: Da. Sica et al., Pharmacokinetics and blood pressure response of losartan in end-stage renal disease, CLIN PHARMA, 38(6), 2000, pp. 519-526
Authors:
Keane, WF
Citation: Wf. Keane, Proteinuria: Its clinical importance and role in progressive renal disease, AM J KIDNEY, 35(4), 2000, pp. S97-S105
Authors:
Molitch, ME
DeFronzo, RA
Franz, MJ
Keane, WF
Mogensen, CE
Parving, HH
Steffes, MW
Citation: Me. Molitch et al., Diabetic nephrology, DIABET CARE, 23, 2000, pp. S69-S72
Authors:
Keane, WF
Citation: Wf. Keane, The role of lipids in renal disease: Future challenges, KIDNEY INT, 57, 2000, pp. S27-S31
Authors:
Massy, ZA
Kim, Y
Guijarro, C
Kasiske, BL
Keane, WF
O'Donnell, MP
Citation: Za. Massy et al., Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: Effects of oxidation and modulation by lovastatin, BIOC BIOP R, 267(2), 2000, pp. 536-540
Authors:
Keane, WF
Citation: Wf. Keane, Lipids and progressive renal disease: The cardio-renal link, AM J KIDNEY, 34(2), 1999, pp. XLIII-XLVI
Authors:
Keane, WF
Eknoyan, G
Citation: Wf. Keane et G. Eknoyan, Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): A position paper of the national kidney foundation, AM J KIDNEY, 33(5), 1999, pp. 1004-1010
Authors:
Keane, WF
Swan, SK
Grimes, I
Humphries, TJ
Citation: Wf. Keane et al., Rabeprazole: Pharmacokinetics and tolerability in patients with stable, end-stage renal failure, J CLIN PHAR, 39(9), 1999, pp. 927-933
Authors:
Keane, WF
Yukawa, S
Mune, M
Citation: Wf. Keane et al., Lipids and renal disease - Introduction, KIDNEY INT, 56, 1999, pp. S1-S1
Authors:
Oda, H
Keane, WF
Citation: H. Oda et Wf. Keane, Recent advances in statins and the kidney, KIDNEY INT, 56, 1999, pp. S2-S5
Authors:
Massy, ZA
Guijarro, C
O'Donnell, MP
Kim, YK
Kashtan, CE
Egido, J
Kasiske, BL
Keane, WF
Citation: Za. Massy et al., The central role of nuclear factor-kappa B in mesangial cell activation, KIDNEY INT, 56, 1999, pp. S76-S79